Patient-Reported Cognitive Impairment among Women with Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results from TAILORx

Lynne I. Wagner, Robert J. Gray, Joseph A. Sparano, Timothy J. Whelan, Sofia F. Garcia, Betina Yanez, Amye J. Tevaarwerk, Ruth C. Carlos, Kathy S. Albain, John A. Olson, Matthew P. Goetz, Kathleen I. Pritchard, Daniel F. Hayes, Charles E. Geyer, E. Claire Dees, Worta J. McCaskill-Stevens, Lori M. Minasian, George W. Sledge, David Cella

Research output: Contribution to journalArticlepeer-review

59 Scopus citations


PURPOSE Cancer-related cognitive impairment (CRCI) is common during adjuvant chemotherapy and may persist. TAILORx provided a novel opportunity to prospectively assess patient-reported cognitive impairment among women with early breast cancer who were randomly assigned to chemoendocrine therapy (CT+E) versus endocrine therapy alone (E), allowing us to quantify the unique contribution of chemotherapy to CRCI. METHODS Women with a 21-gene recurrence score of 11 to 25 enrolled in TAILORX were randomly assigned to CT+E or E. Cognitive impairment was assessed among a subgroup of 552 evaluable women using the 37-item Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) questionnaire, administered at baseline, 3, 6, 12, 24, and 36 months. The FACT-Cog included the 20-item Perceived Cognitive Impairment (PCI) scale, our primary end point. Clinically meaningful changes were defined a priori and linear regression was used to model PCI scores on baseline PCI, treatment, and other factors. RESULTS FACT-Cog PCI scores were significantly lower, indicating more impairment, at 3, 6, 12, 24, and 36 months compared with baseline for both groups. The magnitude of PCI change scores was greater for CT+E than E at 3 months, the prespecified primary trial end point, and at 6 months, but not at 12, 24, and 36 months. Tests of an interaction between menopausal status and treatment were nonsignificant. CONCLUSION Adjuvant CT+E is associated with significantly greater CRCI compared with E at 3 and 6 months. These differences abated over time, with no significant differences observed at 12 months and beyond. These findings indicate that chemotherapy produces early, but not sustained, cognitive impairment relative to E, providing reassurance to patients and clinicians in whom adjuvant chemotherapy is indicated to reduce recurrence risk.

Original languageEnglish (US)
Pages (from-to)1875-1886
Number of pages12
JournalJournal of Clinical Oncology
Issue number17
StatePublished - Jun 10 2020


  • Aged
  • Antineoplastic Agents, Hormonal/adverse effects
  • Antineoplastic Combined Chemotherapy Protocols/adverse effects
  • Aromatase Inhibitors/adverse effects
  • Breast Neoplasms/drug therapy
  • Chemotherapy, Adjuvant
  • Cognitive Dysfunction/chemically induced
  • Cyclophosphamide/administration & dosage
  • Docetaxel/administration & dosage
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local/genetics
  • Randomized Controlled Trials as Topic
  • Tamoxifen/adverse effects

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Patient-Reported Cognitive Impairment among Women with Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results from TAILORx'. Together they form a unique fingerprint.

Cite this